参考文献/References:
[1]Curigliano GCardinale D,Dent S,et al. Cardiotoxicity of anticancer treatments:Epidemiology,detection,and management[J].?CA Cancer J Clin,2016,66(4):309-325.
[2]Pappachan JM,Tun NN,Arunagirinathan G,et al. Pheochromocytomas and Hypertension[J].?Curr Hypertens Rep,2018,20(1):3.
[3]Rossi GP,Bernini G,Caliumi C,et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients[J].?J Am Coll Cardiol,2006,48(11):2293-2300.
[4]Nieman LK. Hypertension and cardiovascular mortality in patients with Cushing syndrome[J].?Endocrinol Metab Clin North Am,2019,48(4):717-725.
[5]Buonacera A,Stancanelli B,Malatino L. Endocrine tumors causing arterial hypertension:pathophysiological mechanisms and clinical implications[J].?High Blood Press Cardiovasc Prev,2017,24(3):217-229.?
[6]Schiffl H,Lang SM. Hypertension secondary to PHPT:cause or coincidence?[J].?Int J Endocrinol,2011,2011:974647.
[7]Fraeman KH,Nordstrom BL,Luo W,et al. Incidence of new-onset hypertension in cancer patients:a retrospective cohort study[J].?Int J Hypertens,2013,2013:379252.
[8]Totzeck M,Mincu RI,Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab:a meta-analysis of more than 20?000 patients[J].?J Am Heart Assoc,2017,6(8):e006278.
[9]Chari A,Stewart AK,Russell SD,et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials[J].?Blood Adv,2018,2(13):1633-1644.
[10]Sagstuen H,Aass N,Foss? SD,et al. Blood pressure and body mass index in long-term survivors of testicular cancer[J].?J Clin Oncol,2005,23(22):4980-4990.
[11]Wirth LJ,Sherman E,Robinson B,et al. Efficacy of selpercatinib in?RET-altered thyroid cancers[J].?N Engl J Med,2020,383(9):825-835.
[12]Dickerson T,Wiczer T,Waller A,et al. Hypertension and incident cardiovascular events following ibrutinib initiation[J].?Blood,2019,134(22):1919-1928.
[13]van Dorst DCH,Dobbin SJH,Neves KB,et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients[J].?Circ Res,2021,128(7):1040-1061.
[14]Herrmann J,Saguner AM,Versari D,et al. Chronic proteasome inhibition contributes to coronary atherosclerosis[J].?Circ Res,2007,101(9):865-874.
[15]Nuver J,De Haas EC,van Zweeden M,et al. Vascular damage in testicular cancer patients:a study on endothelial activation by bleomycin and cisplatin in vitro[J].?Oncol Rep,2010,23(1):247-253.
[16]Boyle SM,Berns JS. Erythropoietin and resistant hypertension in CKD[J].?Semin Nephrol,2014,34(5):540-549.
[17]Grosser T,Ricciotti E,FitzGerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs[J].?Trends Pharmacol Sci,2017,38(8):733-748.?
[18]U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0[EB/OL]. (2017-11-27)[2018-02-23]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
[19]高血压联盟(中国),中国医疗保健国际交流促进会高血压分会,中国高血压防治指南修订委员会,等. 中国血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):-62.
[20]Maitland ML,Bakris GL,Black HR,et al. Initial assessment,surveillance,and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors[J].?J Natl Cancer Inst,2010,102(9):596-604.
[21]Virani SA,Dent S,Brezden-Masley C,et al. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy[J].?Can J Cardiol,2016,32(7):831-841.
[22]Zamorano JL,Lancellotti P,Rodriguez Mu?oz D,et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:?The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J,2016,37(36):2768-2801.
[23]Cohen JB,Geara AS,Hogan JJ,et al. Hypertension in Cancer Patients and Survivors:Epidemiology,Diagnosis,and Management[J]. JACC CardioOncol,2019,1(2):238-251.
[24]Guimaraes DA,Batista RIM,Tanus-Santos JE. Nitrate and nitrite-based therapy to attenuate cardiovascular remodelling in arterial hypertension[J].?Basic Clin Pharmacol Toxicol,2021,128(1):9-17.?
[25]Penttil? P,Rautiola J,Poussa T,et al. Angiotensin inhibitors as treatment of sunitinib/pazopanib-induced hypertension in?metastatic renal cell carcinoma[J]. Clin Genitourin Cancer,2017,15(3):384-390.e3.
[26]Ivanyi P,Beutel G,Drewes N,et al. Therapy of treatment-related hypertension in metastatic renal-cell cancer patients receiving sunitinib.?clin genitourin cancer[J]. 2017,15(2):280-290.e3.
[27]Wasserstrum Y,Kornowski R,Raanani P,et al. Hypertension in cancer patients treated with anti-angiogenic based regimens[J].?Cardiooncology,2015,1(1):6.
[28]Cameron AC,Touyz RM,Lang NN. Vascular complications of cancer chemotherapy[J].?Can J Cardiol,2016,32(7):852-862.
[29]Thompson LA,Saseen JJ,O’Bryant CL,et al. Claims analysis of hypertension occurrence,severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors[J].?J Oncol Pharm Pract,2015,21(4):258-267.
[30]Fumagalli C,Maurizi N,Marchionni N,et al. β-blockers:their new life from hypertension to cancer and migraine[J].?Pharmacol Res,2020,151:104587.
[31]Dirix LY,Maes H,Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors[J]. Ann Oncol,2007,18(6):1121-1122.
[32]Shimbo D,Artinian NT,Basile JN,et al. Self-measured blood pressure monitoring at home:a joint policy statement from the American Heart Association and American Medical Association[J]. Circulation,2020,142(4):e42-e63.?
[33]Bamias A,Manios E,Karadimou A,et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer[J].?Eur J Cancer,2011,47(11):1660-1668.
[34]Costa LJ,Varella PC,Del Giglio A. White coat effect in breast cancer patients undergoing chemotherapy[J].?Eur J Cancer Care (Engl),2003,12(4):372-373.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(1):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(1):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(1):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(1):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(1):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(1):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(1):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]